Michel Perron
About
Michel Perron is a scholar working on Epidemiology, Virology and Immunology.
According to data from OpenAlex, Michel Perron has authored 36 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Epidemiology, 16 papers in Virology and 15 papers in Immunology. Recurrent topics in Michel Perron's work include HIV Research and Treatment (16 papers), Immune Cell Function and Interaction (11 papers) and interferon and immune responses (10 papers). Michel Perron is often cited by papers focused on HIV Research and Treatment (16 papers), Immune Cell Function and Interaction (11 papers) and interferon and immune responses (10 papers). Michel Perron collaborates with scholars based in United States, United Kingdom and Switzerland. Michel Perron's co-authors include Joseph Sodroski, Matthew Stremlau, Christopher M. Owens, Michael K. Kießling, Patrick Autissier, Byeongwoon Song, Hassan Javanbakht, Mark N. Lee, Felipe Diaz‐Griffero and Donovan J. Anderson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Michel Perron
34 papers receiving 4.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michel Perron United States | 25 | 2.8k | 2.0k | 1.7k | 1.6k | 1.1k | 36 | 4.7k | ||
| Tatsuo Shioda Japan | 45 | 3.3k 1.2× | 1.9k 1.0× | 2.1k 1.2× | 2.9k 1.8× | 1.4k 1.2× | 218 | 6.6k | ||
| Louis M. Mansky United States | 35 | 2.5k 0.9× | 1.0k 0.5× | 989 0.6× | 2.3k 1.4× | 1.8k 1.6× | 116 | 5.3k | ||
| Thomas Muster Austria | 30 | 2.0k 0.7× | 3.2k 1.6× | 2.8k 1.7× | 1.7k 1.0× | 1.6k 1.4× | 51 | 6.1k | ||
| Ruth M. Ruprecht United States | 43 | 4.3k 1.5× | 2.5k 1.2× | 1.8k 1.1× | 2.1k 1.3× | 1.4k 1.2× | 179 | 6.6k | ||
| Jacqueline D. Reeves United States | 31 | 2.9k 1.0× | 1.8k 0.9× | 1.1k 0.6× | 2.9k 1.8× | 883 0.8× | 62 | 5.2k | ||
| Zhi-Yong Yang United States | 39 | 2.2k 0.8× | 2.4k 1.2× | 2.1k 1.3× | 3.1k 1.9× | 2.1k 1.8× | 54 | 7.0k | ||
| Ruth I. Connor United States | 34 | 4.0k 1.4× | 2.4k 1.2× | 1.1k 0.7× | 2.7k 1.7× | 1.0k 0.9× | 63 | 5.5k | ||
| Théodora Hatziioannou United States | 40 | 3.7k 1.3× | 2.3k 1.2× | 2.4k 1.5× | 2.9k 1.8× | 1.9k 1.6× | 65 | 7.3k | ||
| Shan‐Lu Liu United States | 40 | 1.0k 0.4× | 1.5k 0.7× | 927 0.6× | 2.0k 1.2× | 1.1k 1.0× | 107 | 4.5k | ||
| Fei Guo China | 32 | 1.5k 0.5× | 1.3k 0.6× | 868 0.5× | 1.6k 1.0× | 1.8k 1.6× | 100 | 4.1k |
Countries citing papers authored by Michel Perron
Since
Specialization
Citations
This map shows the geographic impact of Michel Perron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Perron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Perron more than expected).
Fields of papers citing papers by Michel Perron
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michel Perron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Perron. The network helps show where Michel Perron may publish in the future.
Co-authorship network of co-authors of Michel Perron
This figure shows the co-authorship network connecting the top 25 collaborators of Michel Perron. A scholar is included among the top collaborators of Michel Perron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Perron. Michel Perron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pedersen, Niels C., Michel Perron, Michael J. Bannasch, et al.. (2019). Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. Journal of Feline Medicine and Surgery. 21(4). 271–281.
2.
Murphy, Brian G., Michel Perron, Eisuke Murakami, et al.. (2018). The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Veterinary Microbiology. 219. 226–233.
3.
Stray, Kirsten M., Yeojin Park, Darius Babusis, et al.. (2017). Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. Antiviral Research. 140. 116–120.
4.
Cheng, Guofeng, Tian Yang, Brian Doehle, et al.. (2016). In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir. Antimicrobial Agents and Chemotherapy. 60(3). 1847–1853.
5.
Feng, Joy Y., Yili Xu, Ona Barauskas, et al.. (2015). Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy. 60(2). 806–817.
6.
Jordan, Robert, Matt X. G. Shao, Richard L. Mackman, et al.. (2015). Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection. Antimicrobial Agents and Chemotherapy. 59(8). 4889–4900.
7.
McCutcheon, Krista, Rachel Jordan, Sarah L. Noton, et al.. (2015). The Interferon Type I/III Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells Can Be Attenuated or Amplified by Antiviral Treatment. Journal of Virology. 90(4). 1705–1717.
8.
Clarke, Michael O., Richard L. Mackman, Daniel Byun, et al.. (2015). Discovery of β-d-2′-deoxy-2′-α-fluoro-4′-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. Bioorganic & Medicinal Chemistry Letters. 25(12). 2484–2487.
9.
Diaz‐Griffero, Felipe, Michel Perron, Kathleen McGee-Estrada, et al.. (2008). A human TRIM5α B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology. 378(2). 233–242.
10.
Perron, Michel, et al.. (2007). Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction. Virology. 363(2). 245–255.
11.
Diaz‐Griffero, Felipe, Alak Kanti Kar, Michel Perron, et al.. (2007). Modulation of Retroviral Restriction and Proteasome Inhibitor-Resistant Turnover by Changes in the TRIM5α B-Box 2 Domain. Journal of Virology. 81(19). 10362–10378.
12.
Stremlau, Matthew, Michel Perron, Mark N. Lee, et al.. (2006). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proceedings of the National Academy of Sciences. 103(14). 5514–5519.
13.
Stremlau, Matthew, Byeongwoon Song, Hassan Javanbakht, Michel Perron, & Joseph Sodroski. (2006). Cyclophilin A: An auxiliary but not necessary cofactor for TRIM5α restriction of HIV-1. Virology. 351(1). 112–120.
14.
Javanbakht, Hassan, Ping An, Bert Gold, et al.. (2006). Effects of human TRIM5α polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology. 354(1). 15–27.
15.
Blouse, Grant E., et al.. (2005). Enthalpy measurement using calorimetry shows a significant difference in potential energy between the active and latent conformations of PAI-1. Biological Chemistry. 386(2). 111–6.
16.
Stremlau, Matthew, et al.. (2005). Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5α Determines the Potency of Human Immunodeficiency Virus Restriction. Journal of Virology. 79(5). 3139–3145.
17.
Stremlau, Matthew, Christopher M. Owens, Michel Perron, et al.. (2004). The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature. 427(6977). 848–853.
18.
Miller, Cathy L., John S. L. Parker, Jason B. Dinoso, et al.. (2004). Increased Ubiquitination and Other Covariant Phenotypes Attributed to a Strain- and Temperature-Dependent Defect of Reovirus Core Protein μ2. Journal of Virology. 78(19). 10291–10302.
19.
Perron, Michel, Grant E. Blouse, & Joseph D. Shore. (2003). Distortion of the Catalytic Domain of Tissue-type Plasminogen Activator by Plasminogen Activator Inhibitor-1 Coincides with the Formation of Stable Serpin-Proteinase Complexes. Journal of Biological Chemistry. 278(48). 48197–48203.
20.
Blouse, Grant E., et al.. (2002). A Concerted Structural Transition in the Plasminogen Activator Inhibitor-1 Mechanism of Inhibition. Biochemistry. 41(40). 11997–12009.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tatsuo Shioda Breakdown of academic impact, for papers by Louis M. Mansky Breakdown of academic impact, for papers by Thomas Muster Breakdown of academic impact, for papers by Ruth M. Ruprecht Breakdown of academic impact, for papers by Jacqueline D. Reeves Breakdown of academic impact, for papers by Zhi-Yong Yang Breakdown of academic impact, for papers by Ruth I. Connor Breakdown of academic impact, for papers by Théodora Hatziioannou Breakdown of academic impact, for papers by Shan‐Lu Liu Breakdown of academic impact, for papers by Fei Guo